Postoperative Management of Pulmonary Arterial Hypertension After Surgical Closure of Hypertensive Ventricular Septal Defect in Pediatrics

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
Moataz Rezk ◽  
Ibrahim Kasab ◽  
Basem abdelgawad ◽  
Mohammed Saleh ◽  
Eman Abdelrahman ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Ventricular Septal Defect ◽  
Arterial Hypertension ◽  
Septal Defect ◽  
Postoperative Management ◽  
Surgical Closure ◽  
Pulmonary Arterial

Comparison between milrinone and milrinone with sildenafil in children with ventricular septal defect and pulmonary arterial hypertension

2012 ◽  
Vol 29 ◽  
pp. 159
Author(s):  
M. Andrade Souki ◽  
M. Nacur Lorentz ◽  
B. Silviano Brandão Vianna ◽  
E. Guimarães Heyden ◽  
L. A. Reis Lazarini ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Ventricular Septal Defect ◽  
Arterial Hypertension ◽  
Septal Defect ◽  
Pulmonary Arterial

scholarly journals Role of Endothelin-1 Receptor Antagonist in Reducing Perioperative Pulmonary Arterial Hypertension after Surgical Correction of Ventricular Septal Defect

2016 ◽  
Vol 9 (1) ◽  
pp. 55-59
Author(s):  
Rampada Sarker ◽  
ASMS Islam ◽  
SC Mandal ◽  
Kazi Abul Hasan ◽  
Manoz Kumar Sarker ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Ventricular Septal Defect ◽  
Arterial Pressure ◽  
Arterial Hypertension ◽  
Septal Defect ◽  
Pulmonary Arterial Pressure ◽  
Surgical Correction ◽  
Endothelin 1 ◽  
Pulmonary Arterial

Background: This study was designed to determine the role of oral ambrisentan, an endothelin-1 receptor, in reducing perioperative pulmonary arterial hypertension during surgical correction of ventricular septal defect.Methods: This study was carried out among 54 patients of ventricular septal defect with pulmonary arterial hypertension undergoing surgical correction. The patients were divided into two groups; study group received oral ambrisentan, an endothelin-1 receptor antagonist peri-operatively, starting one week before surgery. Pulmonary arterial pressure was measured by echocardiography, cardiac catheterization and directly from pulmonary artery during surgical procedure.Results: Pulmonary arterial pressure was reduced significantly in the group in which oral amrisentan was given perioperatively. There was further reduction of pulmonary arterial pressure at discharge from hospital and at one month follow-up.Conclusion: Oral ambrisentan can reduce pulmonary arterial pressure perioperatively in patients underwent surgical correction of ventricular septal defect.Cardiovasc. j. 2016; 9(1): 55-59

Sign in / Sign up

Export Citation Format

Share Document